Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in difficult-to-treat atopic asthma
NCT00096954Phase 4Completed
- Sponsor
- Genentech
- Start
- Feb 2006
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Omalizumab with Placebo (2 arms). Primary endpoint: Rate of Asthma Exacerbations Over the 24 Week Treatment Period. Started Feb 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00096954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096954.